India's troubled Ipca buys U.S. API maker

Ipca Labs
India's Ipca Laboratories, which has had drugs from three Indian plants banned from the U.S., bought a North Carolina API maker.

An Indian company that has had its drugs banned by the FDA has bought a contract manufacturing operation in the U.S.

Ipca Laboratories announced Wednesday that it has paid $9.65 million to acquire Pisgah Labs, an API maker based in Pisgah Forest, North Carolina. It said the Pisgah operations would “dovetail” well with operations of its Onyx Scientific unit, a U.K. early stage API maker that it acquired in 2011.

RELATED: FDA warning to Ipca Labs shines light on rampant data falsification

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

The FDA in 2015 put the drugs from Ipca’s API plant and two formulations plants in India on its import alerts list after inspections uncovered rampant data manipulations. In a warning letter issued for the three plants in 2016, the FDA said it found Ipca employees regularly deleted failed testing data from computers and overwrote them with data that indicated APIs and products met standards.

The FDA said Ipca senior management had been told as early as 2013 about what was happening, but “failed to take sufficient corrective action and prevent the recurrence of these problems." One manager acknowledged ordering an employee to backdate records.


Suggested Articles

Sanofi has restarted production at a plant where manufacturing had to be halted to fix pollution issues.

Allogene Therapeutics is looking to use donated T cells that may simplify the very complex CAR T treatment manufacturing processes.

A CDMO that has made a habit of snapping up Big Pharma’s discarded manufacturing plants has put a former AstraZeneca plant into bankruptcy.